Subjective complaints may cause patients to stop treatment after switching to a biosimilar

18 October 2017

A biosimilar is a biological medicine that shows no clinically meaningful differences with another already approved biological medicine (the 'reference medicine'). A new study in *Arthritis & Rheumatology* found that one-quarter of patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from reference infliximab to biosimilar infliximab (called CT-P13) stopped taking CT-P13 during six months follow-up, mainly due to subjective health complaints.

The substantial discontinuation rate of CT-P13 after open-label transitioning might be explained by the awareness of clinicians and patients of the transition. This awareness might induce negative expectations about transitioning to a biosimilar, resulting in negative symptoms during treatment (nocebo effect) and/or incorrect causal attributions.

"As a result, communication between clinicians and patients seems to be the determining factor of the success of transitioning to a biosimilar in daily practice", said lead author Dr. Lieke Tweehuysen, of Sint Maartenskliniek, in the Netherlands.


Provided by Wiley


This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no